[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Yau T, Leong CH, Chan WK, Chan JK, Liang RH, Epstein RJ: A case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO). Cancer Chemother Pharmacol; 2008 Apr;61(4):717-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO).
  • Here we report an unusual case of mixed Wilms' tumour and angiosarcoma in a 38-year-old female patient who presented with haematuria and right lower back pain.
  • Histopathology revealed differentiated adult Wilms' tumour with renal angiosarcoma, whereas the pathology of the para-aortic lymph node and bone metastasis revealed angiosarcoma only.
  • This case suggests that highly angiogenic tumours such as angiosarcoma may be effectively palliated using agents usually reserved for refractory Wilms' tumour, and supports the view that adult Wilms' tumour is more sensitive to such agents.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemangiosarcoma / drug therapy. Kidney Neoplasms / drug therapy. Wilms Tumor / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carboplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis. Neoplasm Recurrence, Local. Platelet Count. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571263.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


2. Patel SR: Radiation-induced sarcoma. Curr Treat Options Oncol; 2000 Aug;1(3):258-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced sarcoma.
  • Radiation-induced sarcomas can originate in either the irradiated bone or soft tissues.
  • The most common histologic subtypes are malignant fibrous histiocytoma (MFH) and osteosarcoma, although other histologies (eg, angiosarcoma, rhabdomyosarcoma) can occur.
  • Radiation-induced sarcomas (either MFH or osteosarcoma) originating in bone should be approached with primary chemotherapy followed by a margin-negative excision similar to de novo bone sarcomas.
  • The dose-intensity of the active agents should be adjusted appropriately for the age, performance status, and prior therapy in a given patient.
  • [MeSH-major] Bone Neoplasms / therapy. Neoplasms, Radiation-Induced / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1995 Aug;9(4):825-40 [7490244.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2818-25 [8874344.001]
  • [Cites] Lab Invest. 1998 Jun;78(6):727-33 [9645763.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2789-95 [10561354.001]
  • [Cites] Arch Surg. 1992 Dec;127(12):1379-85 [1365680.001]
  • [Cites] Cancer. 1971 Nov;28(5):1087-99 [5288429.001]
  • [Cites] Cancer. 1948 May;1(1):3-29 [18867438.001]
  • [Cites] Am J Clin Oncol. 1998 Jun;21(3):317-21 [9626808.001]
  • [Cites] Cancer. 1957 Jan-Feb;10(1):72-88 [13413802.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 20;80(4):233-40 [3280809.001]
  • (PMID = 12057168.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


3. Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, Inbar M: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol; 2000;45(2):177-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
  • PATIENTS AND METHODS: A group of 18 symptomatic heavily pretreated patients with sarcomas of bone or soft tissue received one induction course of gemcitabine at a dose of 1000 mg/m(2) per week for 7 consecutive weeks, followed by 1 week rest.
  • One partial response (leiomyosarcoma) and one minimal response (angiosarcoma) were observed, yielding a true objective response rate of 5.5%.
  • CONCLUSION: Gemcitabine was found to be effective in achieving stabilization and even a minimal response of soft tissue or bone sarcoma refractory to standard chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Bone Neoplasms / drug therapy. Chondrosarcoma / drug therapy. Deoxycytidine / analogs & derivatives. Leiomyosarcoma / drug therapy. Osteosarcoma / drug therapy. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10663634.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


Advertisement
4. Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, Hogendoorn PC, Marreaud S, Van Glabbeke M, Blay JY: Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer; 2008 Nov;44(16):2433-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.
  • Paclitaxel appears to induce tumour control in a higher proportion of patients with angiosarcoma, as compared to other sarcomas.
  • METHOD: Clinical data from patients with angiosarcomas of soft tissue treated with single agent paclitaxel were collected from the centres of the soft tissue and bone sarcoma group of EORTC, using a standardised data collection form.
  • Eleven (34%) patients had been irradiated before as treatment for angiosarcoma.
  • In 8 (25%) patients, the angiosarcoma occurred at sites of prior radiation therapy for other malignancies.
  • CONCLUSION: Paclitaxel was found to be an active agent in angiosarcoma of soft tissue in this retrospective analysis.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Hemangiosarcoma / drug therapy. Paclitaxel / therapeutic use. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Facial Neoplasms / drug therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Retrospective Studies. Scalp. Skin Neoplasms / drug therapy. Young Adult


5. Kudva R, Perveen S, Janardhana A: Primary epithelioid angiosarcoma of bone: a case report with immunohistochemical study. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):811-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary epithelioid angiosarcoma of bone: a case report with immunohistochemical study.
  • Primary malignant vascular tumors of the bone are exceedingly rare and represent <1% of primary malignant bone tumors.
  • Angiosarcoma is a malignant mesenchymal neoplasm in which the neoplastic cells demonstrate endothelial differentiation.
  • Epithelioid angiosarcoma (EA) is a rare variant of angiosarcoma that is characterized by large cells with an epithelioid morphology.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Hemangiosarcoma / diagnosis. Hemangiosarcoma / pathology. Sarcoma / diagnosis. Sarcoma / pathology. Tibia / pathology
  • [MeSH-minor] Amputation. Antigens, CD34 / analysis. Antineoplastic Agents / therapeutic use. Drug Therapy / methods. Fatal Outcome. Histocytochemistry. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Microscopy. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045426.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents
  •  go-up   go-down


6. Asmane I, Litique V, Heymann S, Marcellin L, M├ętivier AC, Duclos B, Bergerat JP, Kurtz JE: Adriamycin, cisplatin, ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma. Analysis of three case reports and review of the literature. Anticancer Res; 2008 Sep-Oct;28(5B):3041-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adriamycin, cisplatin, ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma. Analysis of three case reports and review of the literature.
  • Angiosarcoma represents 1 to 2% of soft tissue tumors.
  • The outcome of angiosarcoma is poor for those patients in whom aggressive surgery cannot be considered.
  • We report three cases of angiosarcoma in which first-line chemotherapy with adriamycin 40 mg/m2 day 1, ifosfamide 3 g/m2 day 1-2, cisplatin 35 mg/m2 day 1-2 and paclitaxel 175 mg/m2 day 3 led to clinically meaningful responses.
  • We emphasize the need for designing trials specifically dedicated to angiosarcomas, as this rare and severe condition may be a target for new antiangiogenic drugs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Hemangiosarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031953.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


7. Vaiphei K, Singh V, Varma S: Splenic angiosarcoma presenting with jaundice, ascites and bone marrow fibrosis. Sarcoma; 2003;7(3-4):183-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic angiosarcoma presenting with jaundice, ascites and bone marrow fibrosis.
  • A middle aged chronic alcoholic presented with deep jaundice, markedly enlarged and tender spleen with leukoerythroblastic blood picture and bone marrow biopsy showing mild fibrosis.
  • Histology revealed morphology of an angiosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2000 Aug;59(2):98-9 [10971165.001]
  • [Cites] South Med J. 2001 Jun;94(6):640-3 [11440334.001]
  • [Cites] Pediatr Hematol Oncol. 1993 Apr-Jun;10(2):151-5 [8318370.001]
  • [Cites] Am J Clin Oncol. 1994 Dec;17(6):502-5 [7977169.001]
  • [Cites] Drug Alcohol Depend. 1987 Mar;19(2):177-80 [3582168.001]
  • (PMID = 18521385.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395525
  •  go-up   go-down






Advertisement